Mesothelioma Treatment
Mesothelioma Cancer
- Causes of Mesothelioma
- Mesothelioma Symptoms
- Mesothelioma Diagnosis
- Mesothelioma Stages
- Mesothelioma Treatment
- Innovative Mesothelioma Treatments
- Managing Mesothelioma Pain
- Nutrition Information for Mesothelioma Patients
- Specialized Mesothelioma Care
- Mesothelioma Risks
- Mesothelioma Support Groups
- Find a Mesothelioma Attorney
- Mesothelioma News
Mesothelioma Directory
Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma
Get Help Today
Looking for help or additional information? Contact us today.| Conditions: | Mesothelioma |
| Start Date: | September 1, 2007 |
| Phase: | Phase II |
| Status: | Completed |
| NCT ID: | NCT00407459 |
| Study Type: | Interventional |
| Intervention: | Drug: Bevacizumab, Pemetrexed, Carboplatin |
| Study Design: | Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | Istituto Clinico Humanitas |
| Ages: | Adult|Senior |
| Enrollment: | 34 |
| Funded By: | Other |
| First Received: | December 4, 2006 |
| End Date: | September 1, 2009 |
| Last Updated: | September 1, 2010 |
| Last Verified: | September 1, 2010 |